RNA interference mediated inhibition of aurorakinase B and its combinations as anticancer therapy
This invention relates to the use of short nucleic acid molecules that modulate Aurora-B kinase (AurkB) expression. The invention includes compounds, compositions and methods useful for the modulation of expression and activity of genes involved in the AurkB pathway. In one embodiment, the present invention provides short nucleic acid molecules, such as siRNA, which can be used in treating, preventing, or inhibiting cancer, and any other proliferative disease, trait or condition, which respond to a reduction in AurkB expression in a cell or tissue. Such short nucleic acid molecules can be used alone or in combination with other treatments or therapies, including short nucleic acid molecules that modulate expression of EGFR.
1. A composition comprising a short nucleic acid molecule that modulates AurkB expression, wherein the short nucleic acid molecule comprises a nucleotide sequence that is complementary to the entire sequence of SEQ ID NO: 3 and is up to 30 nucleotides in length.
2. The composition of claim 1 , wherein the short nucleic acid molecule comprises a sense strand and an antisense strand, wherein the sense strand comprises SEQ ID NO: 11 and the antisense strand comprises SEQ ID NO: 12.
3. The composition of claim 1 , further comprising a second short nucleic acid molecule that modulates the expression of EGFR.
4. The composition of claim 3 , wherein the second short nucleic acid molecule comprises a nucleotide sequence that is complementary to SEQ ID NO: 6.
5. The composition of claim 3 , wherein the second short nucleic acid molecule comprises a sense strand and an antisense strand, wherein the sense strand comprises SEQ ID NO: 17 and the antisense strand comprises SEQ ID NO: 18.
6. The composition of claim 1 , further comprising a pharmaceutically acceptable earner.
7. The composition of claim 1 , further comprising a lipid.
8. The composition of claim 1 , wherein the short nucleic acid molecule is conjugated to cholesterol.
9. The composition of claim 3 , further comprising a pharmaceutically acceptable carrier.
10. A composition comprising a short nucleic acid molecule that modulates AurkB expression, wherein the short nucleic acid molecule is 22-30 nucleotides in length, wherein at least 22 consecutive nucleotides in the molecule are 100% complementary to at least 22 consecutive nucleotides in SEQ ID NO: 3.